Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellectis S.A., a foreign private issuer headquartered in Paris, France, on May 6, 2024. The report covers the month of May 2024 and primarily serves to incorporate by reference a Press Release dated May 6, 2024 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The provided filing text does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts as a conduit for the press release rather than a standalone financial statement.
Material Changes
The filing text does not provide details on material changes versus prior periods. Any significant updates are contained within the referenced Press Release (Exhibit 99.1), the content of which is not included in the input text.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, or unusual items are not detailed in the provided text. The document confirms the incorporation of the May 6, 2024 Press Release into the company's registration statements on Form F-3 and Form S-8 but does not summarize the substance of that release.
Key Facts for Investor Verification
- Verify the content of the Press Release dated May 6, 2024 (Exhibit 99.1), as this filing relies entirely on that document for substantive information.
- Confirm the specific operational or clinical updates intended by the CEO, André Choulika, which are not summarized in the Form 6-K cover page.
- Review the company's active registration statements (Form F-3 No. 333-265826 and various Form S-8 filings) to understand how this press release impacts ongoing capital raising or equity plans.